Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Septerna, Inc.NASDAQ: SEPN
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 47.8% from a year ago
Cash & equivalents stood at $167.12M at the end of Q3 FY2026, down 47.8% from a year earlier and up 97.4% from the prior quarter. Over 3 fiscal years it compounded at +58.0% a year.
Context
- Cash & equivalents amounted to 27.0% of total assets at the end of Q3 FY2026, down 25.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -47.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 120.72M USD
- Year-over-year change
- -49.3%
- 3-year CAGR
- +58.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.72M | -49.3% |
| FY2024 | 2024-12-31 | 238.2M | +169.2% |
| FY2023 | 2023-12-31 | 88.48M | +189.1% |
| FY2022 | 2022-12-31 | 30.61M | — |
Cash & Equivalents vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 cash & equivalents of $167.12M is the 3rd highest of the 7 companies compared; the peer median is $146M.
- Its year-over-year change of -47.8% is the lowest of 6, against a peer median of +24.6%.
- Cash & equivalents amounts to 27.0% of total assets for SEPN, versus a peer median of 39.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $272.64M | +85.4% | +212.9% | 19.1% | |
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M | -47.8% | +58.0% | 27.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M | -27.5% | +46.0% | 32.3% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $130.3M | — | — | 10.8% |
| Mar 2026 | $98.09M | +215.8% | +94.3% | 99.3% | |
| Mar 2026 | $44.69M | +24.6% | -20.7% | 96.4% | |
| Peer median (excluding SEPN) | $146M | +24.6% | +46.0% | 39.8% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.